Stereotactic body radiotherapy (SABR) for limited metastases
Official title: Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer
Run by Samsung Medical Center · NCT07121335 · Data updated 2026-11-12
This program tries stereotactic body radiotherapy (SABR) in people with up to five oligometastatic or oligoprogressive cancer lesions to see if it controls disease better, affects symptoms and side effects, and changes ctDNA in the blood.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | March 31, 2030 |
| Registry record updated | August 13, 2025 |
| Trial ID | NCT07121335 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with metastatic cancer who have up to five oligometastatic or oligoprogressive lesions, ECOG 0–2, no prior radiotherapy to the planned SABR site, and imaging confirming lesions within four weeks are eligible.
✕Probably not a fit
Patients with prior radiotherapy to the planned treatment site or with concurrent brain metastases are excluded and unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort of patients with oligometastatic or oligoprogressive cancer who receive SABR to up to five lesions. Patients must have ECOG performance status 0–2 and imaging within four weeks confirming eligible lesions. Outcomes tracked include progression-free survival, local failure rate, physician-assessed toxicity, patient-reported outcomes, and serial circulating tumor DNA (ctDNA) dynamics. Data will be used to describe safety, clinical outcomes, quality-of-life changes, and potential ctDNA biomarkers associated with response.
Why it matters
Potential benefit: If successful, the study could support use of SABR to improve local control and quality of life and help identify ctDNA signals that predict benefit.
How similar studies have gone: Randomized and cohort studies of SABR in oligometastatic disease have shown promising improvements in disease control and survival, while using ctDNA as a predictive biomarker remains novel and less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Performance status (ECOG PS) 0-2 * Diagnosed with metastatic disease * Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions) Exclusion Criteria: * Patient with a history of prior radiotherapy to the site planned for SABR * Patients with concomitant brain metastases
Where it's running
-
Samsung medical center
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Nalee Kim, MD, PhD
- Email: nalee.kim@samsung.com
- Phone: 82-2-3410-2612
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases
This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.
-
Stereotactic body radiation therapy for spinal metastases with epidural compression
This study tests whether SBRT can safely help adults with spinal metastases that compress the spinal cord see if the treatment works in reducing issues from their cancer.
-
Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer
This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.
-
Plasma ctDNA methylation-guided adjuvant chemotherapy for stage I / low-risk stage II colorectal cancer
This trial will test whether using a blood test for ctDNA methylation one month after surgery to guide adjuvant chemotherapy (such as capecitabine) helps clear ctDNA and lower recurrence risk in adults with stage I or low-risk stage II colorectal cancer who are ctDNA-positive.
-
Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.
This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.
-
Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer
This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.